s2.pdf (215.42 kB)
0/0

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Download (215.42 kB)
journal contribution
posted on 09.01.2014 by Jin-Xiu Yang, Yan-Yun Pan, You-Yang Zhao, Xing-Xiang Wang
A growing body of evidence in animal models and clinical studies supports the concept that endothelial progenitor cell (EPC)-mediated therapy ameliorates pulmonary arterial hypertension (PAH) and thus may represent a novel approach to treat it. Conversely, several experimental findings suggest that EPCs may be involved in PAH pathogenesis and disease progression. These discrepant results confuse the application of EPC transplantation as an effective treatment strategy for PAH. To improve the study of EPC transplantation in PAH therapy, it is high time that we resolve this dilemma. In this review, we examine the pathobiological changes of PAH, the characteristics of EPCs, and the underlying mechanisms of EPC effects on PAH.

Funding

This work was supported by the National Natural Science Foundation of China (grant numbers NSFC 30801500, 81070040) and Program for New Century Excellent Talents in University (grant number NCET-08–0488).

History

Publisher Statement

© 2013 by the Cognizant Communication Corporation, Cell Transplantation

Publisher

Cognizant Communication Corporation

Language

en_US

issn

0963-6897

Issue date

01/01/2013

Exports

Categories

Exports